Expression of mutant p53 in melanoma.
Mutant p53 has been noted in a variety of human malignancies including carcinomas of lung, breast, and colon, which have also been reported to have frequent karyotype anomalies involving the locus of the p53 gene (17p13). Whereas chromosomal abnormalities of chromosomes 1, 6, and 7 have been noted previously in melanoma, frequent aberrations in chromosome 17 have not been reported previously. Due to the common mutation of this locus in so many types of neoplasms, a range of melanomas from different stages of tumor progression were examined immunohistochemically for expression of mutant p53, in order to assess its prevalence and consider the role of this oncogene in the biological progression of melanoma. Forty-five of 53 (85%) specimens from a range of primary and metastatic melanomas were found to have detectable evidence of p53 gene mutation, by virtue of the immunohistochemical detection of mutant p53 protein. Significantly increased prevalence of mutant p53 was found in metastatic melanoma, compared with primary tumors (P less than 0.05). These findings represent one of the highest incidences of this oncogenic mutation yet recorded in a human malignancy and support the concept that p53 may have a functional role in development of the metastatic tumor phenotype.
Nuffield Department of Surgery, University of Oxford, Radcliffe Infirmary, UK.
J R
JR
Stretch
K C
KC
Gatter
E
E
Ralfkiaer
D P
DP
Lane
A L
AL
Harris
D000911:Antibodies, Monoclonal; D002886:Chromosomes, Human, Pair 17; D015870:Gene Expression; D016158:Genes, p53; D006801:Humans; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D012878:Skin Neoplasms / Q000235:genetics* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000235:genetics
D000911:Antibodies, Monoclonal; D016159:Tumor Suppressor Protein p53